Managing novel therapies and concomitant medications in chronic lymphocytic leukemia: key challenges
The treatment of chronic lymphocytic leukemia (CLL) consists of the continuous use of Bruton tyrosine kinase inhibitors (BTKis) such as ibrutinib, acalabrutinib, zanubrutinib and pirtobrutinib, or Bcl-2 inhibitors, such as venetoclax. Overall survival (OS) and progression-free survival (PFS) of CLL...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1517972/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841561000474574848 |
|---|---|
| author | Sofija Kozarac Jelena Ivanovic Marko Mitrovic Kristina Tomic Vujovic Isidora Arsenovic Nada Suvajdzic-Vukovic Nada Suvajdzic-Vukovic Andrija Bogdanovic Andrija Bogdanovic Ana Vidovic Ana Vidovic Milena Todorovic-Balint Milena Todorovic-Balint Jelena Bila Jelena Bila Mirjana Mitrovic Mirjana Mitrovic Danijela Lekovic Danijela Lekovic Irena Djunic Irena Djunic Marijana Virijevic Marijana Virijevic Aleksandar Trivic Aleksandar Trivic Jelena Micic Jelena Micic Darko Antic Darko Antic |
| author_facet | Sofija Kozarac Jelena Ivanovic Marko Mitrovic Kristina Tomic Vujovic Isidora Arsenovic Nada Suvajdzic-Vukovic Nada Suvajdzic-Vukovic Andrija Bogdanovic Andrija Bogdanovic Ana Vidovic Ana Vidovic Milena Todorovic-Balint Milena Todorovic-Balint Jelena Bila Jelena Bila Mirjana Mitrovic Mirjana Mitrovic Danijela Lekovic Danijela Lekovic Irena Djunic Irena Djunic Marijana Virijevic Marijana Virijevic Aleksandar Trivic Aleksandar Trivic Jelena Micic Jelena Micic Darko Antic Darko Antic |
| author_sort | Sofija Kozarac |
| collection | DOAJ |
| description | The treatment of chronic lymphocytic leukemia (CLL) consists of the continuous use of Bruton tyrosine kinase inhibitors (BTKis) such as ibrutinib, acalabrutinib, zanubrutinib and pirtobrutinib, or Bcl-2 inhibitors, such as venetoclax. Overall survival (OS) and progression-free survival (PFS) of CLL patients are significantly improved with the use of these therapies. Adverse effects (AEs) that can occur during treatment and the presence of pre-existing comorbidities in patients can influence subsequent treatment outcomes and, consequently, OS and PFS. Managing these AEs, including cardiologic toxicity and infections (including fungal infections), as well as treating cardiovascular and other comorbidities, can be challenging due to potential drug interactions with the medications used for the management of AEs and comorbidities. Therefore, this review examined the key challenges associated with the concomitant use of novel CLL therapies and medications for managing comorbidities and AEs. This review aims to enhance and facilitate the management of patients with CLL. |
| format | Article |
| id | doaj-art-d2a9e242f2c24772afc81acd79f22cf9 |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-d2a9e242f2c24772afc81acd79f22cf92025-01-03T06:47:28ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-01-011510.3389/fphar.2024.15179721517972Managing novel therapies and concomitant medications in chronic lymphocytic leukemia: key challengesSofija Kozarac0Jelena Ivanovic1Marko Mitrovic2Kristina Tomic Vujovic3Isidora Arsenovic4Nada Suvajdzic-Vukovic5Nada Suvajdzic-Vukovic6Andrija Bogdanovic7Andrija Bogdanovic8Ana Vidovic9Ana Vidovic10Milena Todorovic-Balint11Milena Todorovic-Balint12Jelena Bila13Jelena Bila14Mirjana Mitrovic15Mirjana Mitrovic16Danijela Lekovic17Danijela Lekovic18Irena Djunic19Irena Djunic20Marijana Virijevic21Marijana Virijevic22Aleksandar Trivic23Aleksandar Trivic24Jelena Micic25Jelena Micic26Darko Antic27Darko Antic28Clinic of Hematology, University Clinical Centre of Serbia, Belgrade, SerbiaClinic of Hematology, University Clinical Centre of Serbia, Belgrade, SerbiaClinic of Hematology, University Clinical Centre of Serbia, Belgrade, SerbiaClinic of Hematology, University Clinical Centre of Serbia, Belgrade, SerbiaClinic of Hematology, University Clinical Centre of Serbia, Belgrade, SerbiaClinic of Hematology, University Clinical Centre of Serbia, Belgrade, SerbiaFaculty of Medicine, University of Belgrade, Belgrade, SerbiaClinic of Hematology, University Clinical Centre of Serbia, Belgrade, SerbiaFaculty of Medicine, University of Belgrade, Belgrade, SerbiaClinic of Hematology, University Clinical Centre of Serbia, Belgrade, SerbiaFaculty of Medicine, University of Belgrade, Belgrade, SerbiaClinic of Hematology, University Clinical Centre of Serbia, Belgrade, SerbiaFaculty of Medicine, University of Belgrade, Belgrade, SerbiaClinic of Hematology, University Clinical Centre of Serbia, Belgrade, SerbiaFaculty of Medicine, University of Belgrade, Belgrade, SerbiaClinic of Hematology, University Clinical Centre of Serbia, Belgrade, SerbiaFaculty of Medicine, University of Belgrade, Belgrade, SerbiaClinic of Hematology, University Clinical Centre of Serbia, Belgrade, SerbiaFaculty of Medicine, University of Belgrade, Belgrade, SerbiaClinic of Hematology, University Clinical Centre of Serbia, Belgrade, SerbiaFaculty of Medicine, University of Belgrade, Belgrade, SerbiaClinic of Hematology, University Clinical Centre of Serbia, Belgrade, SerbiaFaculty of Medicine, University of Belgrade, Belgrade, SerbiaFaculty of Medicine, University of Belgrade, Belgrade, SerbiaClinic for Otorhinolaryngology and Maxillofacial Surgery, University Clinical Centre of Serbia, Belgrade, SerbiaFaculty of Medicine, University of Belgrade, Belgrade, SerbiaClinic for Obstetrics and Gynecology, University Clinical Centre of Serbia, Belgrade, SerbiaClinic of Hematology, University Clinical Centre of Serbia, Belgrade, SerbiaFaculty of Medicine, University of Belgrade, Belgrade, SerbiaThe treatment of chronic lymphocytic leukemia (CLL) consists of the continuous use of Bruton tyrosine kinase inhibitors (BTKis) such as ibrutinib, acalabrutinib, zanubrutinib and pirtobrutinib, or Bcl-2 inhibitors, such as venetoclax. Overall survival (OS) and progression-free survival (PFS) of CLL patients are significantly improved with the use of these therapies. Adverse effects (AEs) that can occur during treatment and the presence of pre-existing comorbidities in patients can influence subsequent treatment outcomes and, consequently, OS and PFS. Managing these AEs, including cardiologic toxicity and infections (including fungal infections), as well as treating cardiovascular and other comorbidities, can be challenging due to potential drug interactions with the medications used for the management of AEs and comorbidities. Therefore, this review examined the key challenges associated with the concomitant use of novel CLL therapies and medications for managing comorbidities and AEs. This review aims to enhance and facilitate the management of patients with CLL.https://www.frontiersin.org/articles/10.3389/fphar.2024.1517972/fullchronic lymphocytic leukemiaBruton tyrosine kinase inhibitorsvenetoclaxdrug-drug interactionscomorbidities |
| spellingShingle | Sofija Kozarac Jelena Ivanovic Marko Mitrovic Kristina Tomic Vujovic Isidora Arsenovic Nada Suvajdzic-Vukovic Nada Suvajdzic-Vukovic Andrija Bogdanovic Andrija Bogdanovic Ana Vidovic Ana Vidovic Milena Todorovic-Balint Milena Todorovic-Balint Jelena Bila Jelena Bila Mirjana Mitrovic Mirjana Mitrovic Danijela Lekovic Danijela Lekovic Irena Djunic Irena Djunic Marijana Virijevic Marijana Virijevic Aleksandar Trivic Aleksandar Trivic Jelena Micic Jelena Micic Darko Antic Darko Antic Managing novel therapies and concomitant medications in chronic lymphocytic leukemia: key challenges Frontiers in Pharmacology chronic lymphocytic leukemia Bruton tyrosine kinase inhibitors venetoclax drug-drug interactions comorbidities |
| title | Managing novel therapies and concomitant medications in chronic lymphocytic leukemia: key challenges |
| title_full | Managing novel therapies and concomitant medications in chronic lymphocytic leukemia: key challenges |
| title_fullStr | Managing novel therapies and concomitant medications in chronic lymphocytic leukemia: key challenges |
| title_full_unstemmed | Managing novel therapies and concomitant medications in chronic lymphocytic leukemia: key challenges |
| title_short | Managing novel therapies and concomitant medications in chronic lymphocytic leukemia: key challenges |
| title_sort | managing novel therapies and concomitant medications in chronic lymphocytic leukemia key challenges |
| topic | chronic lymphocytic leukemia Bruton tyrosine kinase inhibitors venetoclax drug-drug interactions comorbidities |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2024.1517972/full |
| work_keys_str_mv | AT sofijakozarac managingnoveltherapiesandconcomitantmedicationsinchroniclymphocyticleukemiakeychallenges AT jelenaivanovic managingnoveltherapiesandconcomitantmedicationsinchroniclymphocyticleukemiakeychallenges AT markomitrovic managingnoveltherapiesandconcomitantmedicationsinchroniclymphocyticleukemiakeychallenges AT kristinatomicvujovic managingnoveltherapiesandconcomitantmedicationsinchroniclymphocyticleukemiakeychallenges AT isidoraarsenovic managingnoveltherapiesandconcomitantmedicationsinchroniclymphocyticleukemiakeychallenges AT nadasuvajdzicvukovic managingnoveltherapiesandconcomitantmedicationsinchroniclymphocyticleukemiakeychallenges AT nadasuvajdzicvukovic managingnoveltherapiesandconcomitantmedicationsinchroniclymphocyticleukemiakeychallenges AT andrijabogdanovic managingnoveltherapiesandconcomitantmedicationsinchroniclymphocyticleukemiakeychallenges AT andrijabogdanovic managingnoveltherapiesandconcomitantmedicationsinchroniclymphocyticleukemiakeychallenges AT anavidovic managingnoveltherapiesandconcomitantmedicationsinchroniclymphocyticleukemiakeychallenges AT anavidovic managingnoveltherapiesandconcomitantmedicationsinchroniclymphocyticleukemiakeychallenges AT milenatodorovicbalint managingnoveltherapiesandconcomitantmedicationsinchroniclymphocyticleukemiakeychallenges AT milenatodorovicbalint managingnoveltherapiesandconcomitantmedicationsinchroniclymphocyticleukemiakeychallenges AT jelenabila managingnoveltherapiesandconcomitantmedicationsinchroniclymphocyticleukemiakeychallenges AT jelenabila managingnoveltherapiesandconcomitantmedicationsinchroniclymphocyticleukemiakeychallenges AT mirjanamitrovic managingnoveltherapiesandconcomitantmedicationsinchroniclymphocyticleukemiakeychallenges AT mirjanamitrovic managingnoveltherapiesandconcomitantmedicationsinchroniclymphocyticleukemiakeychallenges AT danijelalekovic managingnoveltherapiesandconcomitantmedicationsinchroniclymphocyticleukemiakeychallenges AT danijelalekovic managingnoveltherapiesandconcomitantmedicationsinchroniclymphocyticleukemiakeychallenges AT irenadjunic managingnoveltherapiesandconcomitantmedicationsinchroniclymphocyticleukemiakeychallenges AT irenadjunic managingnoveltherapiesandconcomitantmedicationsinchroniclymphocyticleukemiakeychallenges AT marijanavirijevic managingnoveltherapiesandconcomitantmedicationsinchroniclymphocyticleukemiakeychallenges AT marijanavirijevic managingnoveltherapiesandconcomitantmedicationsinchroniclymphocyticleukemiakeychallenges AT aleksandartrivic managingnoveltherapiesandconcomitantmedicationsinchroniclymphocyticleukemiakeychallenges AT aleksandartrivic managingnoveltherapiesandconcomitantmedicationsinchroniclymphocyticleukemiakeychallenges AT jelenamicic managingnoveltherapiesandconcomitantmedicationsinchroniclymphocyticleukemiakeychallenges AT jelenamicic managingnoveltherapiesandconcomitantmedicationsinchroniclymphocyticleukemiakeychallenges AT darkoantic managingnoveltherapiesandconcomitantmedicationsinchroniclymphocyticleukemiakeychallenges AT darkoantic managingnoveltherapiesandconcomitantmedicationsinchroniclymphocyticleukemiakeychallenges |